Kailera Therapeutics (KLRA) investor relations material

Executive summary

• Advanced clinical-stage biotech focused on obesity care, progressing four GLP-1-based product candidates, with lead candidate ribupatide injection in global Phase 3 trials and enrollment on track; data expected in 2028.

• Completed IPO in April 2026, raising $662M net proceeds; cash, cash equivalents, and marketable securities totaled $1.17B as of June 30, 2026.

• No product revenue to date; operations funded by equity and convertible securities.

• Expanded executive team with new CTO and Chief Corporate Affairs Officer to support growth.

• Added to the Russell 2000® Index as of June 29, 2026.

Financial highlights

• Net loss of $111.3M for Q2 2026, up from $28.9M in Q2 2025; net loss of $190.2M for the first half of 2026, up from $46.9M year-over-year.

• Operating expenses rose to $121.4M in Q2 2026 (from $30.7M in Q2 2025), driven by R&D and increased headcount.

• R&D expenses for Q2 2026 were $101.1M, up $81.5M year-over-year; G&A expenses for Q2 2026 were $20.3M, up $9.2M year-over-year.

• Interest income increased to $15.7M for H1 2026, reflecting higher cash balances post-IPO.

• Cash, cash equivalents, and marketable securities totaled $1,171.8M as of June 30, 2026, expected to fund operations into mid-2028.

Outlook and guidance

• Cash runway expected to fund operations and multiple clinical milestones into mid-2028, but substantial additional funding will be needed for continued development and commercialization.

• Anticipates continued significant operating losses as clinical programs advance.

• Key upcoming milestones: Phase 2b ribupatide injection data mid-2027, Phase 3 ribupatide injection data in 2028, Phase 3 ribupatide oral trial initiations in H1 2027, KAI-7535 Phase 2 data in 2027, KAI-4729 Phase 1 data in 2027.